Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pixantrone + cytarabine + methylprednisolone + cisplatin
- Development stage
- Phase 2
- Lead developer
- Sobi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Pixantrone + cytarabine + methylprednisolone + cisplatin is a **four-drug chemotherapy combination regimen** primarily investigated as salvage therapy for **relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL)**. This regimen is modeled on the ESHAP protocol, with pixantrone (a DNA-intercalating aza-anthracenedione designed to reduce cardiotoxicity) replacing etoposide. Pixantrone acts as an antineoplastic agent by interfering with DNA replication and repair; cytarabine is an antimetabolite inhibiting DNA synthesis; cisplatin forms DNA crosslinks causing apoptosis; methylprednisolone is a synthetic corticosteroid exerting lympholytic and anti-inflammatory effects. The combination exploits complementary mechanisms to induce cell death in lymphoma cells. It has been studied in phase I/II trials for safety and efficacy, particularly for patients pretreated with anthracyclines, and is considered as a stem cell mobilization regimen as well[1][3][4][5][7].
- Other names
- pixantrone + cytosine arabinoside + methylprednisolone + cisplatin
02
Targets
APEX1 (DNA-apurinic apyrimidinic site lyase)DNA polymerase familyGR (Glucocorticoid receptor)RNAP (Bacterial dna-dependent RNA polymerase)RNR (Ribonucleotide reductase)TOP2B (DNA topoisomerase II beta)DNA interstrand cross-linkTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pixantrone + cytarabine + methylprednisolone + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pixantrone + cytarabine + methylprednisolone + cisplatin.